Merck (MRK): A Slow and Steady Dividend Grower, but Do Better Alternatives Exist?

By |October 31st, 2017|

Blue chip drug makers such as Merck (MRK) have historically been very popular with income investors because of their defensive nature, meaning that drug demand isn’t really affected by economic downturns.

However, what many investors fail to realize is that, while the pharmaceutical industry as a whole may be recession resistant, successful long-term dividend growth […]